Executive summary
Centene’s Q1 2026 results landed roughly $0.50 ahead of its own internal expectations, with adjusted EPS of $3.37 and a 58% beat over Street consensus. The real story is not the magnitude of the beat but what drove it: a third consecutive quarter of Medicaid HBR improvement (93.1%, down 50 bps YoY), outperformance in both Medicare Advantage and PDP, and a Marketplace segment that is in-line on a pre-tax basis despite elevated silver-tier acuity. Full-year guidance was raised to >$3.40 adjusted EPS, with revenue up $1B driven by Texas Medicaid expansion. The dependency heading into Q2 is the June Wakely risk adjustment data, which management expects to confirm a meaningful receivable for Centene’s higher-acuity silver membership. For MA payers: Centene’s broad membership contraction across Marketplace and Medicaid is creating displaced population pools, while its MA portfolio is pivoting toward D-SNPs (now 40% of the book) and a credible path to breakeven in 2027.
Q1 2026 FINANCIAL PERFORMANCE
| Metric | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Total Revenue | $49.9B | $46.6B | +7.1% |
| Premium & Service Revenue | $44.7B | $42.5B | +5.1% |
| Adjusted EPS | $3.37 | $2.90 | +16.2% |
| GAAP EPS | $3.11 | $2.63 | +18.3% |
| Health Benefits Ratio | 87.3% | 87.5% | -20 bps |
| Medicaid HBR | 93.1% | 93.6% | -50 bps |
| Medicare HBR | 84.9% | 86.3% | -140 bps |
| Commercial HBR | 75.3% | 75.0% | +30 bps |
| SG&A Expense Ratio | 7.6% | 7.9% | -30 bps |
| Operating Cash Flow | $4.4B | $1.5B | +193% |
| Days in Claims Payable | 48 days | 49 days | -1 day |
| Debt-to-Capitalization | 43.2% | 39.5% | +370 bps |
MEMBERSHIP
| Segment | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Total Medicaid | 12.43M | 12.96M | -4.1% |
| Marketplace (ACA) | 3.58M | 5.63M | -36.4% |
| Medicare Advantage | ~1M | ~1M | Declining |
| Medicare PDP | 8.78M | 7.87M | +11.6% |
| Total At-Risk | 26.27M | 27.94M | -6.0% |
Strategic Positioning & Key Developments
Medicaid Margin Recovery: Third Consecutive Quarter of Progress
Medicaid HBR of 93.1% improved 50 bps YoY. CEO Sarah London confirmed the improvement reflects both mild flu in the quarter and genuine fundamental outperformance from 18 months of trend management work: UM standardization, clinical program scaling, network optimization, and increasingly aggressive fraud, waste, and abuse efforts. Behavioral health and high-cost drugs remain the top trend drivers, but London noted ‘pockets of deceleration’ in units-per-utilizer within behavioral health. Full-year net trend target is mid-4%, with a composite rate yield of ~4.5% tracking on plan.
Marketplace: Silver Acuity Shift Calls for Risk Adjustment Receivable
Q1 Marketplace HBR was slightly above expectations in silver-tier, driven by higher acuity members who stayed post-eAPTC expiration. The Wakely March data and full Q1 claims experience now support a meaningful risk adjustment receivable for this population. Centene has conservatively booked a ~3% pre-tax Marketplace margin in guidance (vs. original 4% target), not reflecting the full receivable upside. The June Wakely report is the key catalyst. 3.58M members at quarter-end with ~3M+ expected at year-end.
Medicare: MA on Track for 2027 Breakeven, PDP Strong
Medicare segment HBR of 84.9% beat expectations in both MA and PDP. D-SNP membership now represents 40% of the MA portfolio. London noted 2027 MA rates are still ‘below observed medical cost trend’ but maintained a clear path to breakeven. PDP ended Q1 with 8.78M members on favorable specialty drug trends. The 2027 PDP direct subsidy is expected to increase again as the risk model catches up to IRA-driven non-LIS specialty costs.
Balance Sheet Cleanup: $1B Debt Reduction in Q1
Centene reduced debt by $1B in Q1 using PDP receivable sale proceeds to repay 2027 senior notes. Debt-to-cap fell from 46.5% at year-end to 43.2%. $437M of unrestricted cash on hand. Upcoming 2027/2028 maturities ($1.2B and $2.3B respectively) will be refinanced or partially repaid as operating cash generation builds.
Work Requirements: Nebraska Goes First, System Better Prepared Than 2023
Nebraska launches work requirements mid-2026, the only state pulling forward into 2026. Centene’s base assumption embeds ongoing quarterly Medicaid attrition but characterizes work requirements as a ‘smaller, more focused population’ than redetermination. Management is actively incorporating potential acuity shifts into state rate conversations. Broader rollout expected through 2027-2028, not a step-change event.
Key Leadership Quotes
2026 GUIDANCE UPDATE
| Metric | Raised 2026 | Prior 2026 | Commentary |
|---|---|---|---|
| Adjusted EPS | >$3.40 | >$3.00 | +$0.40 raise |
| GAAP EPS | >$2.37 | >$1.97 | Raised |
| Total Revenue | $187.5-$191.5B | $186.5-$190.5B | +$1B raise |
| Prem & Service Revenue | $171.0-$175.0B | $170.0-$174.0B | +$1B (Texas Medicaid) |
| Full-Year HBR | 90.9%-91.7% | 90.9%-91.7% | Unchanged |
| SG&A Ratio | 7.0%-7.6% | 7.1%-7.7% | -10 bps |
| Medicaid Membership Change | ~6% YE-to-YE | ~4% | Revised down |
| Medicaid Rate Yield | ~4.5% | ~4.5% | On track |
KEY RISKS & CONSIDERATIONS
Headwinds
- Marketplace Risk Adjustment Miss: If June Wakely data does not confirm the silver-tier receivable, Centene could be forced to revise Marketplace margins back toward its original payable assumption. Management characterized this downside as smaller than where they started, but any negative surprise here directly pressures the >$3.40 EPS floor.
- Medicaid Rate-Trend Gap Persists: Full-year guidance embeds a ~4.5% composite rate yield against a mid-4% net trend. A 50 bps miss on either side effect approximately $80-100M in operating income. State rate conversations remain ‘constructive’ but are not locked.
- Q4 Structural Loss + Work Requirement Uncertainty: The guided Q4 operating loss from PDP/commercial seasonality leaves little buffer for execution surprises. Nebraska’s mid-2026 work requirement launch is the first proof point for the industry; if attrition or acuity impact exceeds assumptions, 2027 Medicaid bids become more uncertain.
Opportunities
- Marketplace Risk Adjustment Upside: If June Wakely confirms full receivable, management estimates a range wrapping around the original 4% target and potentially higher. At Centene’s $9.5B Marketplace revenue base, even 100 bps of MCR improvement equals roughly $95M in medical margin.
- D-SNP Concentration Creates 2027 Stars Tailwind: D-SNP now at 40% of MA membership. These plans carry a regulatory tailwind from Medicare-Medicaid integration policy and tend to have more stable risk pools than standard MA. Improved Stars performance for 2027 payment year adds revenue upside.
- PDP Direct Subsidy Set to Rise in 2027: The risk model has not yet incorporated IRA-driven non-LIS specialty pharmacy behavior. Centene expects the 2027 direct subsidy to increase materially, improving PDP economics on top of an already strong Q1 start. With 8.78M members, the PDP franchise is the largest in the country.
BOTTOM LINE ASSESSMENT
Centene’s Q1 2026 is the clearest sign yet that its margin recovery agenda is gaining real traction, not just riding macro tailwinds. The Medicaid HBR improvement is entering its third consecutive quarter of progress, the MA portfolio is disciplined and D-SNP-focused, and the PDP business is running ahead of forecast. The >$3.40 EPS guidance raise understates the upside: management has deliberately withheld the full Marketplace risk adjustment receivable from guidance pending June data, and has not baked in continued Medicaid or Medicare outperformance. The risk is real but quantified: a Q4 structural loss, a Marketplace receivable that may only partially materialize, and work requirements that add acuity uncertainty in 2027.
For MA payer competitive intelligence: Centene’s strategy is consolidating around three high-conviction bets. First, Medicaid is fixable through operational discipline, not just rates. Second, D-SNP is the right Medicare product for a company with Centene’s Medicaid footprint. Third, Marketplace margin is recoverable through risk adjustment mechanics once acuity is visible. None of these are growth bets. They are margin recovery bets. That posture keeps Centene out of aggressive AEP competition for 2026-2027, which creates geographic windows for regional MA payers in markets where Centene is rationalizing its standard MA portfolio. The monitoring trigger for Q2 is the June Wakely data on Marketplace risk adjustment, which will either confirm the receivable thesis or force a downward revision that the Street is not fully pricing in.
